Gts Securities LLC Alnylam Pharmaceuticals, Inc. Transaction History

Gts Securities LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 08, 2025	BUY	$224.32 - $326.09 $167,567 - $243,589	747 New	747 $244 Million
Q4 2024 Feb 18, 2025	SELL	$232.27 - $300.43 $1.64 Million - $2.12 Million	-7,040 Reduced 85.82%	1,163 $274 Million
Q3 2024 Nov 13, 2024	BUY	$233.81 - $287.01 $1.66 Million - $2.04 Million	7,107 Added 648.45%	8,203 $2.26 Million
Q2 2024 Aug 14, 2024	BUY	$143.31 - $247.0 $157,067 - $270,712	1,096 New	1,096 $266,000
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $297,672 - $386,456	1,966 New	1,966 $376,000

916

117M

1.25M

1.49M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $55.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.